-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US09077A1060 |
| Industry | Biotechnology |
| Sector | Healthcare |
| PE Ratio | None |
|---|---|
| Beta | -0.09 |
| Market Cap | 82M |
| Target Price | 23.25 |
| Dividend Yield | None |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BMEA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025